These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 28537988)

  • 1. Prevention of Trastuzumab and Anthracycline-induced Cardiotoxicity Using Angiotensin-converting Enzyme Inhibitors or β-blockers in Older Adults With Breast Cancer.
    Wittayanukorn S; Qian J; Westrick SC; Billor N; Johnson B; Hansen RA
    Am J Clin Oncol; 2018 Sep; 41(9):909-918. PubMed ID: 28537988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systematic review and meta-analysis of beta-blockers and renin-angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer.
    Lewinter C; Nielsen TH; Edfors LR; Linde C; Bland JM; LeWinter M; Cleland JGF; Køber L; Braunschweig F; Mansson-Broberg A
    Eur Heart J; 2022 Jul; 43(27):2562-2569. PubMed ID: 34951629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ACEI/ARB and beta-blocker therapies for preventing cardiotoxicity of antineoplastic agents in breast cancer: a systematic review and meta-analysis.
    Gao Y; Wang R; Jiang J; Hu Y; Li H; Wang Y
    Heart Fail Rev; 2023 Nov; 28(6):1405-1415. PubMed ID: 37414918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Neurohormonal Antagonists on Incident Cardiotoxicity in Patients With Breast Cancer.
    Umadat G; Ray J; Cornell L; Pillai D; Gharacholou SM
    Am J Cardiol; 2023 Feb; 188():68-79. PubMed ID: 36473307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statin Exposure and Risk of Heart Failure After Anthracycline- or Trastuzumab-Based Chemotherapy for Early Breast Cancer: A Propensity Score‒Matched Cohort Study.
    Abdel-Qadir H; Bobrowski D; Zhou L; Austin PC; Calvillo-Argüelles O; Amir E; Lee DS; Thavendiranathan P
    J Am Heart Assoc; 2021 Jan; 10(2):e018393. PubMed ID: 33401953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Preventive Role of Angiotensin Converting Enzyme Inhibitors/Angiotensin-II Receptor Blockers and β-Adrenergic Blockers in Anthracycline- and Trastuzumab-Induced Cardiotoxicity.
    Blanter JB; Frishman WH
    Cardiol Rev; 2019; 27(5):256-259. PubMed ID: 31008768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardioprotective effect of renin-angiotensin inhibitors and β-blockers in trastuzumab-related cardiotoxicity.
    Ohtani K; Ide T; Hiasa KI; Sakamoto I; Yamashita N; Kubo M; Tsutsui H
    Clin Res Cardiol; 2019 Oct; 108(10):1128-1139. PubMed ID: 30859381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two-dimensional speckle tracking echocardiography predicts early subclinical cardiotoxicity associated with anthracycline-trastuzumab chemotherapy in patients with breast cancer.
    Arciniegas Calle MC; Sandhu NP; Xia H; Cha SS; Pellikka PA; Ye Z; Herrmann J; Villarraga HR
    BMC Cancer; 2018 Oct; 18(1):1037. PubMed ID: 30359235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.
    Yu AF; Mukku RB; Verma S; Liu JE; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
    Breast Cancer Res Treat; 2017 Nov; 166(1):241-247. PubMed ID: 28710537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lisinopril or Coreg CR in reducing cardiotoxicity in women with breast cancer receiving trastuzumab: A rationale and design of a randomized clinical trial.
    Guglin M; Munster P; Fink A; Krischer J
    Am Heart J; 2017 Jun; 188():87-92. PubMed ID: 28577685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity.
    Pituskin E; Mackey JR; Koshman S; Jassal D; Pitz M; Haykowsky MJ; Pagano JJ; Chow K; Thompson RB; Vos LJ; Ghosh S; Oudit GY; Ezekowitz JA; Paterson DI
    J Clin Oncol; 2017 Mar; 35(8):870-877. PubMed ID: 27893331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefits of antihypertensive medications for anthracycline- and trastuzumab-induced cardiotoxicity in patients with breast cancer: Insights from recent clinical trials.
    Rygiel K
    Indian J Pharmacol; 2016; 48(5):490-497. PubMed ID: 27721532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardioprotective effect of β-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure.
    Seicean S; Seicean A; Alan N; Plana JC; Budd GT; Marwick TH
    Circ Heart Fail; 2013 May; 6(3):420-6. PubMed ID: 23425978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of cardio-protective agents in cardio-preservation in breast cancer patients receiving Anthracyclines ± Trastuzumab: a Meta-analysis of clinical studies.
    Elghazawy H; Venkatesulu BP; Verma V; Pushparaji B; Monlezun DJ; Marmagkiolis K; Iliescu CA
    Crit Rev Oncol Hematol; 2020 Sep; 153():103006. PubMed ID: 32777728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy cardiotoxicity: cardioprotective drugs and early identification of cardiac dysfunction.
    Di Lisi D; Leggio G; Vitale G; Arrotti S; Iacona R; Inciardi RM; Nobile D; Bonura F; Novo G; Russo A; Novo S
    J Cardiovasc Med (Hagerstown); 2016 Apr; 17(4):270-5. PubMed ID: 25501904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer.
    Guglin M; Krischer J; Tamura R; Fink A; Bello-Matricaria L; McCaskill-Stevens W; Munster PN
    J Am Coll Cardiol; 2019 Jun; 73(22):2859-2868. PubMed ID: 31171092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personalized Decision Making in Early Stage Breast Cancer: Applying Clinical Prediction Models for Anthracycline Cardiotoxicity and Breast Cancer Mortality Demonstrates Substantial Heterogeneity of Benefit-Harm Trade-off.
    Upshaw JN; Ruthazer R; Miller KD; Parsons SK; Erban JK; O'Neill AM; Demissei B; Sledge G; Wagner L; Ky B; Kent DM
    Clin Breast Cancer; 2019 Aug; 19(4):259-267.e1. PubMed ID: 31175052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally?
    Yoon GJ; Telli ML; Kao DP; Matsuda KY; Carlson RW; Witteles RM
    J Am Coll Cardiol; 2010 Nov; 56(20):1644-50. PubMed ID: 21050974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study.
    Kaboré EG; Guenancia C; Vaz-Luis I; Di Meglio A; Pistilli B; Coutant C; Cottu P; Lesur A; Petit T; Dalenc F; Rouanet P; Arnaud A; Arsene O; Ibrahim M; Wassermann J; Boileau-Jolimoy G; Martin AL; Lemonnier J; André F; Arveux P
    PLoS Med; 2019 Dec; 16(12):e1002989. PubMed ID: 31869400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Body Surface Area and Baseline Blood Pressure Predict Subclinical Anthracycline Cardiotoxicity in Women Treated for Early Breast Cancer.
    Kotwinski P; Smith G; Cooper J; Sanders J; Ma L; Teis A; Kotwinski D; Mythen M; Pennell DJ; Jones A; Montgomery H;
    PLoS One; 2016; 11(12):e0165262. PubMed ID: 27911951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.